{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'orally administered approximately 12 and 6 hours before paclitaxel, diphenhydramine (or its', 'equivalent) 50 mg intravenous 30 to 60 minutes prior to paclitaxel, and cimetidine (300 mg)', 'or ranitidine (50 mg) intravenous 30 to 60 minutes before paclitaxel. The appropriate', 'premedication regimen may be determined by the investigator.', '5.1.2 Increase or Reduction in Dose of the Study Drug(s)', '5.1.2.1 Enfortumab Vedotin', 'Dose reduction to 1 mg/kg (dose level - 1) and to 0.75 mg/kg (dose level - 2) will be allowed', 'depending on the type and severity of toxicity. Subjects requiring a dose reduction may be', 're-escalated by 1 dose level (i.e., subjects reduced to 0.75 mg/kg may only be re-escalated to', '1 mg/kg) provided the toxicity does not require study drug discontinuation and has returned', 'to baseline or VI Grade 1. If the toxicity recurs, re-escalation will not be permitted. Subjects', 'with > Grade 2 corneal AEs will not be permitted to dose re-escalate.', 'EV should not be administered to subjects with CrCl < 30 mL/min. Dose modification', 'recommendations for EV associated toxicity are presented in Table 4 and Table 5', 'Dose', 'interruptions for other EV associated toxicity is permitted at the discretion of the site', 'investigator. Dose interruptions may last up to 8 weeks (2 cycles). Dose interruptions for', 'subjects who are deriving clinical benefit from treatment may be extended beyond 8 weeks, if', \"the subject's toxicity does not otherwise require permanent discontinuation. If there is a dose\", 'interruption, the schedule for response assessments will not be adjusted.', 'Table 4', 'Recommended dose modifications for enfortumab vedotin associated', 'hematologic toxicity*', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Continue at same', 'Continue at same', 'Withhold dose until', 'Withhold dose until', 'dose level.', 'dose level.', 'toxicity is VI Grade 1 or', 'toxicity is VI Grade 1 or', 'For Grade 2', 'has returned to baseline,', 'has returned to baseline,', 'thrombocytopenia,', 'then resume treatment at', 'then reduce dose by 1', 'withhold dose until', 'the same dose level or', 'dose level and resume', 'toxicity is', 'consider dose reduction', 'treatment, or discontinue', 'VI Grade 1 or has', 'by 1 dose level.', 'at the discretion of the', 'returned to baseline,', 'Transfusions or growth', 'investigator. Transfusions', 'then resume', 'factors may be used as', 'or growth factors may be', 'treatment at the', 'indicated per institutional', 'used as indicated per', 'same dose level.', 'guidelines.', 'institutional guidelines.', 'For anemia, treatment', 'discontinuation should be', 'strongly considered.', '*Note: hematological toxicity refers to anemia, thrombocytopenia, neutropenia and febrile neutropenia.', '14 Sep 2020', 'Astellas', 'Page 57 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table 5', 'Recommended dose modifications for enfortumab vedotin associated', 'nonhematologic toxicity', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Continue at same dose', 'Continue at same dose', 'Withhold dose until', 'For Grade 4 AEs,', 'level.', 'level, except in the', 'toxicity is < Grade 1', 'discontinue', 'If ocular symptoms', 'event of Grade 2', 'or has returned to', 'treatment.*', 'and/or changes in', 'neuropathy or corneal', 'baseline, then resume', 'Grade 4 vomiting', 'vision are identified,', 'AEs.', 'treatment at the same', 'and/or diarrhea that', 'the subject should be', 'dose level or consider', 'For Grade 2', 'improves to < Grade 2', 'evaluated with an', 'neuropathy or corneal', 'dose reduction by 1', 'or less within 72 hours', 'ophthalmologic', 'dose level.', \"AE's, withhold dose\", 'with supportive', 'exam.**', 'until toxicity is', 'For Grade 3', 'management does not', 'VI Grade 1 or has', 'neuropathy or corneal', 'require', 'returned to baseline,', 'AEs, discontinue', 'discontinuation.', 'and then resume', 'treatment.', 'treatment at the same', 'For Grade 3', 'dose level. For the', 'hyperglycemia/', 'second occurrence of', 'elevated blood', 'Grade 2 neuropathy or', 'glucose, withhold EV', \"corneal AE's,\", 'treatment. Resume', 'withhold dose until', 'treatment once', 'toxicity is < Grade 1,', 'hyperglycemia/', 'and then reduce the', 'elevated blood glucose', 'dose by 1 dose level', 'has improved to', 'and resume treatment.', '< Grade 2 and subject', 'If ocular symptoms', 'is clinically and', 'and/or changes in', 'metabolically stable.', 'vision are identified,', 'If ocular symptoms', 'the subject should be', 'and/or changes in', 'evaluated with an', 'vision are identified,', 'ophthalmologic', 'the subject should be', 'exam.**', 'evaluated with an', 'ophthalmologic', 'exam.', '**', 'AE: adverse event; EV: enfortumab vedotin', '* Grade 3/4 electrolyte imbalances/laboratory abnormalities, except hyperglycemia, that are not associated with', 'clinical sequelae and/or are corrected with supplementation/appropriate management within 72 hours of their', 'onset do not require discontinuation (e.g., Grade 4 hyperuricemia). Grade 3 rash that is not limiting self-care', 'activities of daily living or associated with infection requiring systemic antibiotics does not require treatment', 'interruption, provided symptoms are not severe and can be managed with supportive treatment.', '**Ophthalmologic exam should be performed by an ophthalmologist. In countries where optometrists can', 'perform exams and prescribe medications, an optometrist may be used instead.', '14 Sep 2020', 'Astellas', 'Page 58 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}